8-K: Perrigo Reports Q2 2026 Results, Reaffirms Outlook

Perrigo Company plc announced its second quarter 2026 financial results, reporting a decrease in net sales and adjusted diluted EPS, while reaffirming its full-year outlook.

Summary

• Perrigo Company plc reported second quarter 2026 financial results from continuing operations.
• All In reported net sales were $1,023 million, a decrease of 3.2% year-over-year.
• Core net sales were $907 million, a decrease of 3.1% year-over-year.
• Core adjusted diluted EPS declined 20.7% to $0.46.
• All In adjusted diluted EPS declined 12.3% to $0.50.
• The company reaffirmed its full-year 2026 outlook, expecting a sequentially stronger second half.
• The Dermacosmetics business was divested, and strategic reviews of Infant Formula and Oral Care are ongoing.
• Market share gains were achieved in key categories despite category softness and macroeconomic headwinds.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly negative report. While the company is executing its strategic plan and gaining market share, the overall net sales and adjusted EPS are down year-over-year, and the company faces ongoing category softness and macroeconomic headwinds.

Positives

• Continued market share gains in key categories across U.S. store-brand OTC and European brands.
• Completion of the Dermacosmetics divestiture, simplifying the company's portfolio.
• Reaffirmed full-year 2026 outlook with expectations for a stronger second half.
• Infant Formula net sales increased 23.1% year-over-year.
• The company is becoming a more focused consumer self-care company.
• Progress in strengthening underlying business fundamentals.
• Debt reduction achieved through proceeds from the Dermacosmetics divestiture.

Negatives

• All In reported net sales decreased by 3.2% to $1,023 million.
• Core net sales decreased by 3.1% to $907 million.
• Core adjusted diluted EPS decreased by 20.7% to $0.46.
• All In adjusted diluted EPS decreased by 12.3% to $0.50.
• Reported All In gross margin decreased by 370 basis points to 30.7%.
• Reported operating margin decreased by 200 basis points to 2.3%.
• Self Care net sales decreased by 3.7%.
• Specialty Care net sales decreased by 2.8%.

Risks

• Ongoing category softness and macroeconomic headwinds impacting results.
• Uncertainty of non-recurring infant formula related charges and timing/amount of restructuring charges.
• Potential adverse changes to U.S. and foreign tax, healthcare, and other government policy.
• Supply chain impacts, including those caused or exacerbated by armed conflict, trade sanctions, and disease.
• Increased or new tariffs and changes in global trade relations.
• Customer acceptance of new products and competition from other industry participants.
• Pricing pressures from customers and consumers.
• Potential costs and reputational impact of product recalls or sales halts.

Future Outlook

The company reaffirms its full-year 2026 outlook, anticipating a sequentially stronger second half. This is expected to be driven by moderation of planned under absorption, more favorable category comparisons, lower interest expense, continued cost benefits from the Operational Enhancement Program, and progress in key growth initiatives.

Management Comments

• "We continued to execute our Three-S plan in the second quarter, strengthening areas of the business within our control, improving operational performance, streamlining our portfolio, and further reducing debt."
• "While results were impacted by ongoing category softness and macroeconomic headwinds, we again drove market share gains as our broad portfolio of quality self-care products across all price points continues to resonate with consumers seeking value and affordability."
• "We are becoming a more focused consumer self-care company, and are making progress in strengthening the underlying fundamentals of our business."
• "Looking ahead, we are reaffirming our full-year 2026 outlook with a sequentially stronger second half, supported by clear and tangible drivers..."
• "While mindful of an uncertain consumer and macroeconomic environment, we are continuing to gain market share, streamline our portfolio, and strengthen our balance sheet."

Industry Context

StockSavvy.ai notes that Perrigo's results reflect broader industry trends of consumer demand for value and affordability amidst macroeconomic challenges. The company's focus on streamlining its portfolio and divesting non-core assets aligns with strategic shifts seen across the consumer staples sector.

Stakeholder Impact

• Shareholders: Declining EPS and net sales may negatively impact shareholder returns, though the reaffirmation of the outlook and focus on long-term value creation could be viewed positively.
• Employees: Operational Enhancement Program benefits may lead to cost efficiencies, but declining sales could create uncertainty.
• Customers: Continued market share gains suggest customer loyalty and resonance with value offerings.
• Suppliers: Potential for reduced order volumes due to lower net sales, but also opportunities with innovation and growth initiatives.

Next Steps

• Continue execution of the Three-S plan.
• Complete strategic reviews of Infant Formula and Oral Care businesses.
• Focus on converting operational progress into sustainable growth and long-term shareholder value.
• Monitor the consumer and macroeconomic environment.

Key Dates

Recommendation

The company is executing a strategic plan and gaining market share, which are positive signs. However, the reported decline in net sales and adjusted EPS, coupled with ongoing macroeconomic headwinds and category softness, warrants a cautious approach. The reaffirmation of the full-year outlook provides some stability, but the negative year-over-year financial performance suggests holding the stock until clearer signs of sustained growth emerge.

Keywords

Consumer Self-Care, OTC, Perrigo, Earnings, Financial Results, Dermacosmetics, Infant Formula, Portfolio Streamlining